SCHEMBL10316622

SCHEMBL10316622

[CH2]CCCCC(C)(C)CCCC

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.31
CPT2 P23786 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25383476 0.97 FFAR1 (0.34) FFAR1CPT2TDP1TSHR
SCHEMBL588096 0.97 FFAR1 (0.34) FFAR1CPT2TDP1TSHR
SCHEMBL8353953 0.97 FFAR1 (0.34) FFAR1CPT2TDP1TSHR
SCHEMBL25385475 0.97 FFAR1 (0.34) FFAR1CPT2TDP1TSHR
SCHEMBL25384743 0.95 TSHR (0.35) TSHR
SCHEMBL25385601 0.92 TSHR (0.40) FFAR1CPT2TDP1TSHR
SCHEMBL25384437 0.92 TSHR (0.40) FFAR1CPT2TDP1TSHR
SCHEMBL25386266 0.92 TSHR (0.40) FFAR1CPT2TDP1TSHR
SCHEMBL5462951 0.92 TSHR (0.40) FFAR1CPT2TDP1TSHR
SCHEMBL25384828 0.92 TSHR (0.40) FFAR1CPT2TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024252-A1 LIPID NANOPARTICLE NITTO DENKO CORPORATION (JP) 2024-01-25 US disclosed
WO-2024018762-A1 PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 WO disclosed
WO-2024018761-A1 NEUTRAL LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 WO disclosed
WO-2023188830-A1 LIPID NANOPARTICLES 国立大学法人北海道大学 2023-10-05 WO disclosed
WO-2023191050-A1 PHARMACEUTICAL COMPOSITION FOR DELIVERY TO CANCER, OR IMMUNOSTIMULATING COMPOSITION 日東電工株式会社 2023-10-05 WO disclosed
EP-4223314-A1 LIPID NANOPARTICLE National University Corporation Hokkaido University (JP) 2023-08-09 EP disclosed
CN-116367718-A Lipid nanoparticles 国立大学法人北海道大学 2023-06-30 CN disclosed
CN-101253183-B Process for preparing optically active diphosphanes BASF SE 2013-07-10 CN disclosed
EP-2520570-A1 AMINOPYRIDINE COMPOUND Ube Industries, Ltd. (JP) 2012-11-07 EP disclosed
US-20120259123-A1 AMINOPYRIDINE COMPOUND UBE INDUSTRIES, LTD. (JP) 2012-10-11 US disclosed
CN-102666490-A Aminopyridine compound UBE INDUSTRIES 2012-09-12 CN disclosed
US-20120226036-A1 SUBSTITUTED CARBONYL COMPOUND UBE INDUSTRIES, LTD. (JP) 2012-09-06 US disclosed
EP-2476678-A1 SUBSTITUTED CARBONYL COMPOUNDS Ube Industries, Ltd. (JP) 2012-07-18 EP disclosed
CN-102548985-A Substituted carbonyl compounds UBE INDUSTRIES 2012-07-04 CN disclosed
CN-101253183-A Process for preparing optically active diphosphanes BASF SE (DE) 2008-08-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024252-A1 LIPID NANOPARTICLE LIPC, ACOX1, ABCB4 FFAR1 359/4885CPT2 427/4885TDP1 4237/4885
US-20120226036-A1 SUBSTITUTED CARBONYL COMPOUND PTGER2, PTGER1, LTB4R2 FFAR1 136/4885CPT2 113/4885TDP1 4750/4885
US-20120259123-A1 AMINOPYRIDINE COMPOUND PTGIS, QDPR, PTGIR FFAR1 2994/4885CPT2 1806/4885TDP1 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.